Breast Cancer PSMA PET

Recruiting Early Phase 1 Interventional Study
Triple Negative Breast Cancer
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinic…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with know…
Contacts

Ahmad Shariftabrizi, M.D.

319-887-4942

ashariftabrizi@uiowa.edu

CONTACT

Elina Shrestha

319 335 0114

eshrestha@uiowa.edu

CONTACT